Regarding therapy in other LFS-associated brain tumors, in Reed et al. a comparative transcriptomics-based precision medicine platform identified STAT1/STAT2 overexpression and ruxolitinib sensitivity in an LFS glioblastoma patient, leading to personalized treatment and disease stabilization.79 Here, STAT1 is linked to brain neoplasm.